Protection of pancreatic β-cells against glucotoxicity by short-term treatment with GLP-1

Biochemical and Biophysical Research Communications

Volumn 459, Issue 4, 2015, Pages 561-567

  Park, Sun Hyun ^a   Park, Jae Hyung ^a   Shim, Hye Min ^a   Na, Ann Yae ^a   Bae, Ki Churl ^a   Lim, Jeung Geun ^a   Song, Dae Kyu ^a  

^a Keimyung University School of Medicine   (South Korea)

Author keywords

Glucagon like peptide 1; Glucotoxiciy FoxO 1; mTOR complex 2; Pancreatic cell; Type 2 diabetes

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCOSE; MULTIPROTEIN COMPLEX; PRIMER DNA; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 2;

ANIMAL; C57BL MOUSE; DRUG EFFECTS; METABOLISM; MOUSE; NUCLEOTIDE SEQUENCE; PANCREAS ISLET; PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALS; BASE SEQUENCE; DNA PRIMERS; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; ISLETS OF LANGERHANS; MICE; MICE, INBRED C57BL; MULTIPROTEIN COMPLEXES; PHOSPHORYLATION; REAL-TIME POLYMERASE CHAIN REACTION; TOR SERINE-THREONINE KINASES;

EID: 84930713441     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2015.02.139     Document Type: Article

References (32)

1. A.E. Butler, J. Janson, S. Bonner-Weir, R. Ritzel, R.A. Rizza, and P.C. Butler Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes Diabetes 52 2003 102 110
2. A.E. Butler, J. Janson, W.C. Soeller, and P.C. Butler Increased beta-cell apoptosis prevents adaptive increase in beta-cell mass in mouse model of type 2 diabetes: evidence for role of islet amyloid formation rather than direct action of amyloid Diabetes 52 2003 2304 2314
3. D. Mathis, L. Vence, and C. Benoist beta-Cell death during progression to diabetes Nature 414 2001 792 798
4. R.P. Robertson, J. Harmon, P.O. Tran, and V. Poitout Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes Diabetes 53 Suppl. 1 2004 S119 S124
5. Z.Q. Hou, H.L. Li, L. Gao, L. Pan, J.J. Zhao, and G.W. Li Involvement of chronic stresses in rat islet and INS-1 cell glucotoxicity induced by intermittent high glucose Mol. Cell. Endocrinol. 291 2008 71 78
6. K.J. Chang-Chen, R. Mullur, and E. Bernal-Mizrachi Beta-cell failure as a complication of diabetes Rev. Endocr. Metab. Disord. 9 2008 329 343
7. D.J. Drucker Glucagon-like peptides Diabetes 47 1998 159 169
8. D.J. Drucker Minireview: the glucagon-like peptides Endocrinology 142 2001 521 527
9. M.E. Doyle, and J.M. Egan Mechanisms of action of glucagon-like peptide 1 in the pancreas Pharmacol. Ther. 113 2007 546 593
10. L. Farilla, H. Hui, C. Bertolotto, E. Kang, A. Bulotta, U. Di Mario, and R. Perfetti Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats Endocrinology 143 2002 4397 4408
11. Y. Li, T. Hansotia, B. Yusta, F. Ris, P.A. Halban, and D.J. Drucker Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis J. Biol. Chem. 278 2003 471 478
12. J. Buteau, W. El-Assaad, C.J. Rhodes, L. Rosenberg, E. Joly, and M. Prentki Glucagon-like peptide-1 prevents beta cell glucolipotoxicity Diabetologia 47 2004 806 815
13. M. Gutniak, C. Orskov, J.J. Holst, B. Ahren, and S. Efendic Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus N. Engl. J. Med. 326 1992 1316 1322
14. M.B. Toft-Nielsen, S. Madsbad, and J.J. Holst Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients Diabetes Care 22 1999 1137 1143
15. T.J. Kieffer, C.H. McIntosh, and R.A. Pederson Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV Endocrinology 136 1995 3585 3596
16. H. Ogata, K. Tokuyama, S. Nagasaka, A. Ando, I. Kusaka, N. Sato, A. Goto, S. Ishibashi, K. Kiyono, Z.R. Struzik, and Y. Yamamoto Long-range correlated glucose fluctuations in diabetes Methods Inf. Med. 46 2007 222 226
17. A. Lim, S.H. Park, J.W. Sohn, J.H. Jeon, J.H. Park, D.K. Song, S.H. Lee, and W.K. Ho Glucose deprivation regulates KATP channel trafficking via AMP-activated protein kinase in pancreatic beta-cells Diabetes 58 2009 2813 2819
18. P. Kuo, R. Chaikomin, A. Pilichiewicz, D. O'Donovan, J.M. Wishart, J.H. Meyer, K.L. Jones, C. Feinle-Bisset, M. Horowitz, and C.K. Rayner Transient, early release of glucagon-like peptide-1 during low rates of intraduodenal glucose delivery Regul. Pept. 146 2008 1 3
19. J. Buteau, M.L. Spatz, and D. Accili Transcription factor FoxO1 mediates glucagon-like peptide-1 effects on pancreatic beta-cell mass Diabetes 55 2006 1190 1196
20. T. Kitamura, J. Nakae, Y. Kitamura, Y. Kido, W.H. Biggs 3rd, C.V. Wright, M.F. White, K.C. Arden, and D. Accili The forkhead transcription factor Foxo1 links insulin signaling to Pdx1 regulation of pancreatic beta cell growth J. Clin. Invest 110 2002 1839 1847
21. T. Ikenoue, K. Inoki, Q. Yang, X. Zhou, and K.L. Guan Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signaling EMBO J. 27 2008 1919 1931
22. Q. Wang, L. Li, E. Xu, V. Wong, C. Rhodes, and P.L. Brubaker Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells Diabetologia 47 2004 478 487
23. D.A. Guertin, D.M. Stevens, C.C. Thoreen, A.A. Burds, N.Y. Kalaany, J. Moffat, M. Brown, K.J. Fitzgerald, and D.M. Sabatini Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1 Dev. Cell. 11 2006 859 871
24. Q. Yang, K. Inoki, T. Ikenoue, and K.L. Guan Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity Genes. Dev. 20 2006 2820 2832
25. A.D. Barlow, J. Xie, C.E. Moore, S.C. Campbell, J.A. Shaw, M.L. Nicholson, and T.P. Herbert Rapamycin toxicity in MIN6 cells and rat and human islets is mediated by the inhibition of mTOR complex 2 (mTORC2) Diabetologia 55 2012 1355 1365
26. H. Hui, A. Nourparvar, X. Zhao, and R. Perfetti Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5'-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway Endocrinology 144 2003 1444 1455
27. J. Buteau, S. Foisy, E. Joly, and M. Prentki Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor Diabetes 52 2003 124 132
28. D.J. Drucker, S.I. Sherman, F.S. Gorelick, R.M. Bergenstal, R.S. Sherwin, and J.B. Buse Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits Diabetes Care 33 2010 428 433
29. M. Elashoff, A.V. Matveyenko, B. Gier, R. Elashoff, and P.C. Butler Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies Gastroenterology 141 2011 150 156
30. M. Monami, C. Lamanna, N. Marchionni, and E. Mannucci Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials Diabetes Care 31 2008 1455 1460
31. V. Rebours, M.C. Boutron-Ruault, M. Schnee, C. Ferec, C. Le Marechal, O. Hentic, F. Maire, P. Hammel, P. Ruszniewski, and P. Levy The natural history of hereditary pancreatitis: a national series Gut 58 2009 97 103
32. N. Jura, H. Archer, and D. Bar-Sagi Chronic pancreatitis, pancreatic adenocarcinoma and the black box in-between Cell. Res. 15 2005 72 77